Intavitreal bevacizumab for choroidal neovascularization in a case of vitelliform macular dystrophy

Chieko Yasuda, Mineo Kondo, Shinji Ueno, Shigeo Yoshida, Tatsuro Ishibashi, Hiroko Terasaki

Research output: Contribution to journalArticlepeer-review


Purpose : To report a case of vitelliform macular dystrophy treated by intavitreal bevacizumab for choroidal neovascularization. Case : A 23-year-old female presented with suddenly impaired vision in her right eye. She had been diagnosed with vitelliform macular dystrophy when seen by an ophthalmologist for ocular trauma 8 years before. Findings : Corrected visual acuity was 0.5 right and 1.2 left. The right eye showed subretinal hemorrhage in the macular area. Fluorescein angiography showed findings suggestive of choroidal neovascularization in the macula. The right eye was treated by two sessions of intravireal bevacizumab at a 4-week interval. Visual acuity in the right eye improved to 1.0 3 months later. She has been doing well for 6 months until present. Conclusion : This case illustrates that intravitreal bevacizumab may be effective for choroidal neovascularization secondary to vitelliform macular dystrophy.

Original languageEnglish
Pages (from-to)1063-1067
Number of pages5
JournalJapanese Journal of Clinical Ophthalmology
Issue number7
Publication statusPublished - Jul 2012

All Science Journal Classification (ASJC) codes

  • Ophthalmology


Dive into the research topics of 'Intavitreal bevacizumab for choroidal neovascularization in a case of vitelliform macular dystrophy'. Together they form a unique fingerprint.

Cite this